NCT03771040 is a Phase 3 clinical trial of Masitinib in Asthma, sponsored by AB Science.

Who is sponsoring NCT03771040?

NCT03771040 is sponsored by AB Science.

What drugs are being tested in NCT03771040?

Interventions in NCT03771040: Masitinib, Placebo.

Is NCT03771040 still recruiting?

NCT03771040 is currently completed. Last updated 7 December 2020.

Last reviewed 2020-12-07 · How we verify

NCT03771040

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, Phase 3 Study to Compare the Efficacy and the Safety of Masitinib Versus Placebo in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

Completed Phase 3 Last updated 7 December 2020

What this trial tests

Phase 3 trial testing Masitinib in Asthma in 347 participants. Completed in 1 September 2020.

Timeline

1 December 2016

Primary endpoint
1 September 2020

1 September 2020

Quick facts

Lead sponsor	AB Science
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	347
Start date	1 December 2016
Primary completion	1 September 2020
Estimated completion	1 September 2020
Sites	5 locations across Argentina, Malaysia, Peru, Philippines, Ukraine

Drugs / interventions tested

Masitinib — full drug profile →
Placebo

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

AB Science — full company profile →

Who can join

Adults 18 to 75, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Severe asthma exacerbation rate
Time frame: Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months
The number of severe asthma exacerbations over time frame of outcome measure

Sponsor's own description

The purpose of this study is to assess the safety and efficacy of masitinib (6 mg/kg/day) in severe persistent asthma, uncontrolled with high dose of inhaled corticosteroid and with elevated eosinophil levels.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons.
Hussain M, Liu G. · · 2024 · cited 60× · PMID 38474348 · DOI 10.3390/cells13050384
Kinase inhibitors in the treatment of obstructive pulmonary diseases.
Defnet AE, Hasday JD, Shapiro P. · · 2020 · cited 17× · PMID 32361678 · DOI 10.1016/j.coph.2020.03.005

Verify or expand the search:

Other trials of Masitinib

Trials testing the same drug.

NCT00789633 — Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer · Phase 3 · completed

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other AB Science trials

Trials by the same sponsor.

NCT07174492 — Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients · Phase 3 · not yet recruiting
NCT05449444 — Masitinib for the Treatment of Severe Mast Cell Activation Syndrome · Phase 2 · unknown
NCT05200169 — Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects · EARLY_PHASE1 · completed
NCT00789633 — Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03771040 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AB Science
Last refreshed: 7 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03771040.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing